<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of cardiac sarcoidosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of cardiac sarcoidosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of cardiac sarcoidosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ron Blankstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Garrick C Stewart, MD MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hugh Calkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J McKenna, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3723224914"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical presentation of cardiac sarcoidosis (CS) ranges from an incidentally discovered condition to heart failure (HF), brady- and tachyarrhythmias, and sudden death.</p><p>The diagnosis of CS is difficult to establish, and as a result, CS is often underrecognized in clinical practice [<a href="#rid1">1</a>]. CS most often occurs as a manifestation of systemic sarcoidosis, although isolated CS can occur in patients who do not have evidence of sarcoidosis in other organs [<a href="#rid2">2</a>]. Yet, commonly used clinical criteria require the diagnosis of extracardiac disease in order to establish the diagnosis of CS in the absence of having a positive endomyocardial biopsy. While endomyocardial biopsy provides a high specificity for diagnosing CS, this invasive test has a limited sensitivity. Furthermore, there is limited understanding of disease progression and a lack of consensus on the optimal methods for disease detection.</p><p>This topic will discuss the clinical manifestations of CS and provide an overview of how to evaluate patients with suspected CS. Management and prognosis of CS and diagnosis and management of systemic sarcoidosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/4365.html" rel="external">"Pathology and pathogenesis of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">"Treatment of pulmonary sarcoidosis: Initial approach"</a> and  <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p class="headingAnchor" id="H1433480339"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Clinically manifest CS has been estimated as occurring in approximately 5 percent of patients with pulmonary/systemic sarcoidosis [<a href="#rid3">3</a>]. However, the true prevalence of CS is uncertain and is likely underestimated since many individuals with CS have nonspecific symptoms or subclinical disease. Autopsy and imaging studies of patients with systemic sarcoidosis have identified evidence of CS in 20 to 29 percent in the United States and as high as 58 to 70 percent in Japan [<a href="#rid3">3-6</a>]. In the United States, 13 to 25 percent of deaths from sarcoidosis have been attributed to CS, while in Japan, 47 to 85 percent of deaths from sarcoidosis have been attributed to cardiac involvement [<a href="#rid7">7</a>].</p><p>The risk of adverse cardiac outcomes in patients with systemic sarcoidosis was illustrated by a study of data from Danish nationwide registries in which 11,834 patients diagnosed with sarcoidosis during 1996 to 2016 (and without heart failure or arrhythmias at baseline) were matched by age, sex, and comorbidities with 47,336 individuals in the population without sarcoidosis [<a href="#rid8">8,9</a>]. Patients with sarcoidosis had higher 10-year risk of heart failure compared with the background population (3.18 versus 1.72 percent) as well as other adverse cardiac events including a composite of ICD implantation, ventricular arrhythmias, and cardiac arrest (0.96 versus 0.45 percent), a composite of pacemaker implantation, atrioventricular block, and sinoatrial dysfunction (0.94 versus 0.51 percent), and atrial fibrillation or flutter (3.44 for sarcoidosis patients versus 2.66 percent). The 10-year risk of mortality was also higher for sarcoidosis patients (10.88 versus 7.43 percent).</p><p>CS can affect patients of all racial backgrounds and ages, with an average age at presentation of approximately 50 years old [<a href="#rid10">10</a>].</p><p>Isolated CS may occur in up to 25 percent of CS cases, and thus the absence of extracardiac sarcoidosis does not rule out CS [<a href="#rid2">2,11</a>].</p><p>Several reports have suggested that the incidence of CS may be increasing [<a href="#rid10">10</a>]; however, it is unclear if such an increase is due to a true increase in the prevalence of disease or to increased awareness and detection of this condition.</p><p>The prevalence of pulmonary sarcoidosis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H1307897246"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Sarcoidosis is a heterogeneous disorder of unknown etiology whose signature lesions are noncaseating granulomata. Sarcoidosis may involve any part of the heart. While the ventricular myocardium is most commonly affected, involvement by the atria, papillary muscles, valves, coronary arteries, and pericardium has been described. Similar to other involved organs, cardiac disease generally progresses from areas of focal inflammation to scar. However, the natural history of CS is not well characterized and is highly variable. Some individuals may only have a small area of inflammation or scar and will not experience any significant clinical sequelae. On the other hand, some patients will progress to develop a pattern of extensive inflammation and scar. Given the limited data on how this disease progresses, it may be preferable to refer to different patterns of CS rather than stages, as use of stages implies a linear progression across different stages.</p><p class="headingAnchor" id="H1340435187"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The most frequent clinical manifestations of CS are atrioventricular (AV) block, arrhythmias, HF, and sudden cardiac death [<a href="#rid10">10,12</a>].</p><p class="headingAnchor" id="H2962139928"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Symptoms and signs of CS include palpitations, presyncope, syncope, fatigue, dyspnea, orthopnea, and sudden cardiac death. Palpitations may be caused by either supraventricular or ventricular arrhythmias. Presyncope or syncope can be caused by AV block, ventricular tachycardia, or supraventricular tachycardia. Fatigue, dyspnea, and orthopnea can reflect HF caused by CS. However, fatigue and dyspnea are nonspecific symptoms that may also result from lung disease in patients with pulmonary sarcoidosis.</p><p>By contrast, angina symptoms are generally considered more suggestive of atherosclerotic coronary artery disease (CAD), as CS less frequently causes angina. (See <a class="local">'Coronary artery disease'</a> below.)</p><p class="headingAnchor" id="H4096267240"><span class="h2">Key manifestations</span><span class="headingEndMark"> — </span>The key clinical manifestations of CS are conduction system disease, tachyarrhythmias, cardiomyopathy, HF, and rarely CAD.</p><p class="headingAnchor" id="H3286366443"><span class="h3">Arrhythmias</span></p><p class="headingAnchor" id="H2541698028"><span class="h4">Conduction system disease</span><span class="headingEndMark"> — </span>AV block is the most common clinical presentation in patients with clinically evident CS. In a retrospective study of 110 patients with histologically confirmed CS, symptomatic heart block was present in 44 percent of patients [<a href="#rid10">10,13</a>]. Complete AV block occurs at a younger age in patients with CS than in individuals with complete AV block due to other etiologies [<a href="#rid14">14</a>]. Prolongation of the PR interval (first-degree AV block) due to disease of the AV node or bundle of His and intraventricular conduction defects are common [<a href="#rid15">15</a>] and may progress. Thus, conduction system disease may initially be silent and then progress to complete AV block [<a href="#rid16">16</a>] and cause syncope or even sudden death [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/907.html" rel="external">"Etiology of atrioventricular block"</a> and  <a class="medical medical_review" href="/z/d/html/911.html" rel="external">"Third-degree (complete) atrioventricular block"</a>.)</p><p class="headingAnchor" id="H4256061904"><span class="h4">Tachyarrhythmias</span><span class="headingEndMark"> — </span>Supraventricular and ventricular tachyarrhythmias are both common in CS.</p><p>Ventricular arrhythmias (sustained or nonsustained ventricular tachycardia and ventricular premature beats [VPBs]) are the second most common clinical presentation of CS, occurring in approximately 30 percent of cases [<a href="#rid10">10</a>]. These arise when sarcoid granulomas within the myocardium become foci for abnormal automaticity, or may disrupt ventricular activation and recovery, causing re-entrant arrhythmias. Scar within the myocardium may also cause re-entrant arrhythmias.</p><p>Supraventricular arrhythmias are a rare presenting feature at the diagnosis of cardiac sarcoidosis but can develop at any time in the clinical course [<a href="#rid18">18</a>]. Supraventricular arrhythmias seen with CS include paroxysmal atrial tachycardia, atrial flutter, atrial fibrillation, and sinus arrest secondary to granulomatous involvement of the sinus node. In a retrospective study that included 100 patients with definite or probable CS, the prevalence of supraventricular arrhythmias over a mean follow-up of 5.8 years was 32 percent, with atrial fibrillation being the most common arrhythmia [<a href="#rid19">19</a>]. The presence of left atrial enlargement by echocardiography was most strongly associated with the development of supraventricular arrhythmias. A high prevalence of atrial arrhythmias in CS was also observed in a study evaluating 135 patients who had ambulatory electrocardiography (ECG) monitoring; patients with systemic sarcoidosis who had late gadolinium enhancement by cardiac magnetic resonance imaging had a threefold increase in the prevalence of atrial arrhythmias compared with those who did not have any evidence of cardiac involvement (36 versus 12 percent) [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H1783310326"><span class="h3">Sudden cardiac death</span><span class="headingEndMark"> — </span>Sudden death due to ventricular tachyarrhythmias or conduction block accounts for 25 to 65 percent of deaths caused by CS [<a href="#rid7">7,21-24</a>]. Some patients with known systemic sarcoidosis develop symptomatic or electrocardiographically evident arrhythmias or conduction abnormalities prior to sarcoid-related sudden death, assisting diagnosis and therapeutic management. However, sudden death can occur in the absence of symptoms or a previous cardiac event [<a href="#rid25">25,26</a>]. In a large CS case series, fatal and aborted sudden cardiac death was the presenting manifestation in 14 percent of CS cases [<a href="#rid24">24</a>]. Thus, a key diagnostic challenge is to identify individuals at risk for sudden death to enable preventive therapies. (See  <a class="medical medical_review" href="/z/d/html/974.html" rel="external">"Pathophysiology and etiology of sudden cardiac arrest"</a> and  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'Management of arrhythmias and conduction system disease'</a>.)</p><p class="headingAnchor" id="H3066357251"><span class="h3">Cardiomyopathy and heart failure</span><span class="headingEndMark"> — </span>Presence of cardiomyopathy or HF in a patient with known extracardiac sarcoidosis should prompt an evaluation for CS. Patients with sarcoidosis are at increased risk of developing HF [<a href="#rid8">8,27</a>]. HF is less common than arrhythmia at initial presentation and is the first clinical manifestation of CS in fewer than 20 percent of cases. However, CS may even be diagnosed after transplant in the explanted hearts of patients thought to have an idiopathic cardiomyopathy.</p><p>CS is a cause of cardiomyopathy, which may manifest with symptoms and signs of HF (eg, orthopnea, edema). CS can cause an arrhythmogenic cardiomyopathy with heart block, supraventricular and ventricular arrhythmia, a dilated cardiomyopathy (with dilated left ventricular [LV] volumes and depressed LV ejection fraction [LVEF], which can lead to HF with reduced ejection fraction), or a restrictive cardiomyopathy (with normal LV volumes and preserved LVEF), which can lead to HF with preserved ejection fraction.</p><p>Fewer data are available on the prevalence and clinical significance of right ventricular (RV) dysfunction attributable to CS [<a href="#rid28">28-30</a>]. Some patients with CS present with signs of predominantly right-sided HF, which can be caused by sarcoid-related inflammation or scar affecting the RV [<a href="#rid31">31</a>] or less commonly secondary to CS involving the tricuspid valve [<a href="#rid32">32</a>]. Right HF due to CS involving the RV should be distinguished from other causes of right HF including pulmonary hypertension secondary to lung disease. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H364103430"><span class="h3">Coronary artery disease</span><span class="headingEndMark"> — </span>Sarcoidosis can involve the coronary arteries with a vasculitis, which has been reported as a rare cause of unstable angina or myocardial infarction [<a href="#rid33">33-35</a>]. A case report described spontaneous coronary artery dissection in a patient with CS [<a href="#rid36">36</a>]. However, patients with CS are more likely to have other, more typical types of CAD.</p><p>As discussed below, CS should be distinguished from ischemic heart disease in patients with symptoms consistent with both disorders. However, it is important to acknowledge that CS and atherosclerotic CAD often coexist. Data are lacking on the frequency of CAD in patients with CS. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H4011457237"><span class="h2">Test findings</span><span class="headingEndMark"> — </span>Preliminary test findings may raise clinical suspicion of CS but are not specific for CS.</p><p>ECG findings in patients with CS include PR interval prolongation, second- or third-degree AV block, QRS prolongation (with or without right bundle branch block or left bundle branch block), frequent VPBs, atrial arrhythmias, pathologic Q waves, and nonspecific ST segment and T wave abnormalities. However, none of these features are specific for CS. The 12-lead ECG has low sensitivity (generally reported as &lt;50 percent) for detection of CS [<a href="#rid17">17,37</a>].</p><p>A chest radiograph is not required to diagnose CS, but it is a component of the diagnosis of pulmonary sarcoidosis. Findings suggestive of HF include cardiomegaly, cephalization of the pulmonary vessels, Kerley B-lines, and pleural effusions. However, these findings are not specific for CS, and absence of these findings does not exclude CS. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Chest radiograph'</a>.)</p><p>Chest radiographic findings in patients with pulmonary sarcoidosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Chest radiograph'</a>.)</p><p>Elevated levels of cardiac troponin, serum angiotensin converting enzyme, serum lysozyme, and urinary calcium have been reported in patients with CS. As an example, in a study of 62 patients presenting with CS, high-sensitivity cardiac troponin T or I was elevated at presentation in 26 of 50 (52 percent) patients in which it was measured [<a href="#rid38">38</a>]. While an incidental finding of an elevated cardiac troponin may prompt evaluation for myocardial disease, these biomarkers do not have a role in screening for CS or in assigning diagnostic probability.</p><p class="headingAnchor" id="H1380580843"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of CS requires appropriate clinical suspicion and often requires integrating clinical and pathologic data together with the results of advanced cardiac imaging.</p><p class="headingAnchor" id="H1426153678"><span class="h2">When to consider cardiac sarcoidosis</span><span class="headingEndMark"> — </span>The diagnosis of CS should be considered in the following patients [<a href="#rid39">39-41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with histologic or clinical diagnosis of extracardiac sarcoidosis, with or without cardiac symptoms, should be evaluated for subclinical, as well as clinical, cardiac involvement (arrhythmias, conduction disease, HF, etc). (See  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adults (age &lt;60 years) with unexplained syncope or unexplained new onset conduction system disease such as sustained second- or third-degree AV block. (See  <a class="medical medical_review" href="/z/d/html/910.html" rel="external">"Second-degree atrioventricular block: Mobitz type II"</a> and  <a class="medical medical_review" href="/z/d/html/911.html" rel="external">"Third-degree (complete) atrioventricular block"</a> and  <a class="medical medical_review" href="/z/d/html/907.html" rel="external">"Etiology of atrioventricular block"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with aborted sudden cardiac death or sustained ventricular tachycardia (VT) not explained by typical outflow tract VT, fascicular VT, or VT due to other structural heart disease such as coronary artery disease (CAD).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with unexplained dilated, restrictive, or arrhythmogenic cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a> and  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a> and  <a class="medical medical_review" href="/z/d/html/3516.html" rel="external">"Causes of dilated cardiomyopathy"</a>.)</p><p></p><p class="headingAnchor" id="H3041226831"><span class="h2">Approach to diagnosis</span><span class="headingEndMark"> — </span>The following approach to the diagnosis of CS is similar to, but different from, the approach described in the 2014 Heart Rhythm Society (HRS) expert consensus statement [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Perform a detailed history and physical along with a 12-lead ECG. (See <a class="local">'Initial evaluation and testing'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with indications for echocardiography or continuous ambulatory ECG (Holter) monitor should undergo both of these tests. The authors do not recommend these tests for routine screening, but some experts suggest routine use of echocardiography [<a href="#rid42">42</a>] and Holter monitoring to evaluate patients with extracardiac sarcoidosis. (See <a class="local">'Holter monitoring'</a> below and <a class="local">'Echocardiography'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based upon presence of specific symptoms, ECG findings, and/or echocardiographic abnormalities, identify candidates for advanced cardiac imaging. (See <a class="local">'Criteria for advanced cardiac imaging'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who do not meet criteria for advanced cardiac imaging require no further immediate evaluation for CS. For patients with extracardiac sarcoidosis, we recommend serial (eg, yearly) clinical reevaluation with ECG to detect development of symptoms and signs of CS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with criteria for advanced imaging, proceed with advanced imaging (cardiovascular magnetic resonance [CMR] and/or <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography [FDG-PET]) based upon local availability and expertise and test results. (See <a class="local">'Selection of advanced imaging'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient lacks histologic confirmation of sarcoidosis, the feasibility of extracardiac or endomyocardial biopsy (EMB) should be assessed. (See <a class="local">'Role of biopsy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Integrate all clinical data and apply diagnostic criteria to identify definite and probable CS. (See <a class="local">'How to diagnose cardiac sarcoidosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with uncertain diagnosis, determine need for and feasibility of further diagnostic evaluation, including EMB. (See <a class="local">'Role of biopsy'</a> below.)</p><p></p><p class="headingAnchor" id="H607015712"><span class="h2">Initial evaluation and testing</span><span class="headingEndMark"> — </span>Patients who have biopsy-proven or clinically diagnosed extracardiac sarcoidosis should undergo evaluation for symptoms and signs of cardiac involvement and an ECG.</p><p>The following symptoms and signs should prompt initial testing with a continuous ambulatory ECG (Holter) monitor and an echocardiogram (see <a class="local">'Holter monitoring'</a> below and <a class="local">'Echocardiography'</a> below). Triggers for initial testing include symptoms such as palpitation, syncope, atypical chest pain, dyspnea, effort intolerance, or physical exam signs such as jugular venous distension, cardiac murmur, S3 or S4 gallop, displaced point of maximal impulse, or unexplained HF. Clinical presentation may be subtle and present with features of arrhythmogenic, dilated, or even restrictive cardiomyopathy. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a>.)</p><p>The authors do not recommend echocardiography for routine screening for CS, but some experts (including the HRS Expert Consensus Statement) suggest echocardiography to evaluate patients with extracardiac sarcoidosis [<a href="#rid42">42</a>], and some experts also suggest continuous ambulatory (Holter) monitoring in such patients.</p><p class="headingAnchor" id="H544337694"><span class="h2">Criteria for advanced cardiac imaging</span><span class="headingEndMark"> — </span>We recommend advanced cardiac imaging (CMR imaging or FDG-PET) for selected patients with or without evidence of extracardiac sarcoidosis.</p><p class="headingAnchor" id="H2978875305"><span class="h3">With extracardiac sarcoidosis</span><span class="headingEndMark"> — </span>The criteria listed here for patients with histologic or clinical evidence of extracardiac sarcoidosis are modified from criteria for patients with histologic evidence of extracardiac sarcoidosis in the 2014 HRS Expert Consensus Statement [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have biopsy-proven or clinically diagnosed extracardiac sarcoidosis <strong>and</strong> one of the following symptoms or signs consistent with (but not specific for) CS [<a href="#rid42">42</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One or more of the following symptoms: prominent palpitations lasting &gt;1 to 2 weeks, presyncope, or syncope.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One or more of the following ECG abnormalities: complete left or right bundle branch block; presence of unexplained pathologic Q waves in two or more leads; sustained first-, second-, or third-degree AV block; or sustained or nonsustained VT.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One or more of the following echocardiographic abnormalities: regional wall motion abnormality, ventricular aneurysm, basal septal thinning, or depressed LVEF. The authors use an LVEF threshold of &lt;50 percent; some experts use an LVEF threshold of &lt;40 percent as described in the consensus statement [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H1396238659"><span class="h3">Without extracardiac sarcoidosis</span><span class="headingEndMark"> — </span>Patients with no prior history of extracardiac sarcoidosis who have one or more of the following conditions are candidates for advanced cardiac imaging:</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained second-degree Mobitz type II or third-degree AV block in adults aged &lt;60 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sustained monomorphic VT in the absence of any known etiology. This criterion was favored by the majority of the 2014 HRS Expert Consensus Statement writing group but was not included as a formal recommendation [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H3088334139"><span class="h2">Patients without criteria for advanced cardiac imaging</span><span class="headingEndMark"> — </span>Patients who lack any of the symptoms or signs that serve as indications for advanced cardiac imaging are unlikely to benefit from further immediate evaluation. In one study of 62 patients with extracardiac sarcoidosis, the presence of at least one cardiac symptom, ECG abnormality, Holter monitor finding, or echocardiographic finding was highly sensitive for CS (100 percent, 95% CI 88-100 percent) [<a href="#rid43">43</a>]. Thus, the probability of CS is low in patients without any criteria for advanced imaging, so further immediate cardiac evaluation is not indicated. Patients with extracardiac sarcoidosis without current symptoms and signs of CS should be followed prospectively with serial (eg, annual) clinical exams and ECG to monitor for potential development of signs and symptoms of CS.</p><p class="headingAnchor" id="H3905151969"><span class="h2">Selection of advanced imaging</span><span class="headingEndMark"> — </span>The choice between CMR, FDG-PET, or both among patients with suspected CS with an indication for advanced imaging is based upon test characteristics, feasibility, and test results.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CMR</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with suspected CS with an indication for advanced cardiac imaging, we recommend CMR imaging with gadolinium-based contrast as the initial diagnostic testing option, unless there are contraindications for performing this test. A similar recommendation on CMR as the preferred initial test has also been made by the American Thoracic Society clinical practice guideline on diagnosis and detection of sarcoidosis [<a href="#rid44">44</a>] and by a joint multi-society European position statement [<a href="#rid45">45</a>]. (See <a class="local">'Cardiovascular magnetic resonance'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with indeterminate FDG-PET results, we recommend performing CMR <strong>after</strong> FDG-PET.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FDG-PET</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If CMR cannot be performed (due to conditions such as renal dysfunction, which is a contraindication for gadolinium-based contrast or presence of an incompatible device), proceed with FDG-PET study as the alternative initial diagnostic test.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We also recommend FDG-PET <strong>after</strong> CMR in the following clinical settings:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If CMR is negative and high clinical suspicion for CS persists. As an example, FDG-PET is suggested for a patient with known extracardiac sarcoidosis and typical signs and/or symptoms of CS as described above (see <a class="local">'Criteria for advanced cardiac imaging'</a> above) with negative CMR.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If CMR is inconclusive due to image quality or nonspecific findings (eg, midwall late gadolinium enhancement [LGE] in a pattern consistent with myocarditis or sarcoidosis, or RV involvement in a pattern that is consistent with arrhythmogenic RV cardiomyopathy or sarcoidosis).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>CMR is strongly suggestive of CS, and a decision is made to treat the patient with immunosuppressive therapy, as described next. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'Identification of inflammation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend performing FDG-PET in patients who are candidates for immunosuppressive therapy for CS. In this setting, FDG-PET would be useful for the following reasons: the presence of myocardial as well as extracardiac inflammation would indicate a greater role for systemic immunosuppressive therapy, and the FDG-PET scan could serve as a baseline upon which to compare future FDG-PET studies to determine response to therapy.</p><p></p><p class="headingAnchor" id="H282930678"><span class="h2">Role of biopsy</span><span class="headingEndMark"> — </span>Since pathologic confirmation (even if extracardiac) provides the most definitive means of identifying CS, efforts should be made to safely obtain a suitable tissue sample in patients with suspected CS who lack histologic confirmation. Biopsy of extracardiac sites may provide a higher yield (greater sensitivity) and lower procedural risk than EMB (which has a sensitivity of approximately 20 to 30 percent). (See  <a class="medical medical_review" href="/z/d/html/4923.html" rel="external">"Endomyocardial biopsy", section on 'Late AV block, arrhythmias, or refractory HF'</a>.)</p><p>For patients with criteria for advanced imaging for CS, we suggest limited whole-body FDG imaging in addition to dedicated cardiac imaging for CS. Such information may be useful for the following reasons: to enhance diagnostic certainty since patients with cardiac findings who have FDG-avid extracardiac involvement in a pattern consistent with sarcoidosis are more likely to have CS, to identify FDG-avid lymph nodes or lung tissue for biopsy that may be higher yield than a cardiac biopsy for establishing a tissue diagnosis, and to obtain data on the presence and severity of extracardiac disease activity (ie, amount of inflammation outside the heart), which may be relevant for decisions on the role of immunosuppressive therapies. The field of view for whole-body imaging should range from the orbits to the upper thigh, and at minimum should include the chest, liver, and spleen, as these are the most frequently affected organs.</p><p>In cases of isolated CS or a negative extracardiac biopsy, EMB is required for definitive diagnosis.</p><p>However, even when biopsy examination does not reveal noncaseating granulomas, as described above, some patients may still have a sufficiently high probability of having CS (see <a class="local">'Probable cardiac sarcoidosis'</a> below) or may have another inflammatory cardiomyopathy for which treatment with immunosuppressive therapy would be warranted, especially patients who are symptomatic, have electrical instability, or who have new LV dysfunction along with findings on FDG-PET imaging consistent with active inflammation. (See <a class="local">'Endomyocardial biopsy'</a> below and  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3534906423"><span class="h2">How to diagnose cardiac sarcoidosis</span><span class="headingEndMark"> — </span>Data from the diagnostic evaluation as described above are integrated to determine the likelihood of CS based on the following diagnostic categories. Data synthesis should include review of advanced cardiac imaging with cardiovascular imaging experts with knowledge and expertise in the use of FDG-PET and CMR for diagnosis of CS.</p><p class="headingAnchor" id="H188577116"><span class="h3">Definite cardiac sarcoidosis</span><span class="headingEndMark"> — </span>A definite diagnosis of CS is established by detection of noncaseating granuloma on histologic examination of myocardial tissue with no alternative cause identified [<a href="#rid42">42</a>]. Since the histologic findings are not pathognomonic, some experts consider the diagnosis of CS "highly probable" if myocardial noncaseating granulomas are detected. [<a href="#rid46">46,47</a>]. Thus, a definite diagnosis of CS is confirmed only if an EMB or other myocardial tissue specimen is available, shows diagnostic findings, and other causes have been excluded.</p><p class="headingAnchor" id="H1585490584"><span class="h3">Uncertain diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of CS is frequently uncertain. The following categories (highly probable, probable, and possible CS) may be used in cases in which there is uncertainty regarding the diagnosis of CS. This classification system, while not widely used for evaluating the likelihood of CS, has been developed based on the World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) organ assessment instrument, which has been used to determine the probability of sarcoidosis organ involvement [<a href="#rid48">48</a>]. Management with immune suppression or a prophylactic implantable cardioverter-defibrillator (ICD) is typically restricted to patients with probable or definite CS. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'Approach to management'</a>.)</p><p class="headingAnchor" id="H2942088870"><span class="h4">Clinical findings suggesting cardiac sarcoidosis</span><span class="headingEndMark"> — </span>For patients with uncertain diagnosis of CS, the presence of one or more of these clinical findings suggests a higher likelihood of CS [<a href="#rid42">42</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained reduced LVEF (&lt;40 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained sustained VT (spontaneous or induced)</p><p class="bulletIndent1"><span class="glyph">●</span>AV block: Mobitz type II second degree or third degree (whether or not responsive to immunosuppressive therapy)</p><p></p><p class="headingAnchor" id="H826170580"><span class="h4">Probable cardiac sarcoidosis</span><span class="headingEndMark"> — </span>The term probable CS denotes a likelihood of CS ≥50 percent. This term recognizes the inherent uncertainty that is often clinically present when evaluating patients with suspected CS. While the HRS consensus statement represents the most contemporary and comprehensive classification system to date, it has a few limitations [<a href="#rid42">42</a>]. First, the criteria categorize CMR and PET results in a binary fashion, yet these tests provide a spectrum of findings. Second, the HRS criteria require a histologic diagnosis of extracardiac sarcoidosis for diagnosis of probable CS.</p><p>Noninvasive criteria for "highly probable" (&gt;90 percent likelihood) CS have not been established. The authors apply this term to cases with histologic or clinical diagnosis of extracardiac sarcoidosis, clinical findings suggesting CS, and imaging findings by CMR or FDG-PET typical for CS, when other potential causes for these findings have been excluded.</p><p class="headingAnchor" id="H3504758795"><span class="h5">With histologic confirmation of extracardiac sarcoidosis</span><span class="headingEndMark"> — </span>When there is confirmation of extracardiac sarcoidosis, we use the criteria for probable CS included in the HRS Expert Consensus Statement [<a href="#rid42">42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Histologic diagnosis of extracardiac sarcoidosis (with no histologic evidence from myocardial tissues).</p><p></p><p class="bulletIndent1"><strong>AND</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One or more of the following cardiac findings:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A clinical finding suggesting CS. (See <a class="local">'Clinical findings suggesting cardiac sarcoidosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any of the following imaging findings typical for CS:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cardiac FDG-PET with patchy uptake in a pattern consistent with CS.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>CMR with LGE in a pattern consistent with CS.</p><p></p><p class="bulletIndent3"><strong>OR</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cardiac <sup>67</sup>gallium diffuse uptake by the heart. However, cardiac gallium scans are no longer performed in most institutions as FDG-PET offers improved diagnostic accuracy.</p><p></p><p class="bulletIndent1"><strong>AND</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other causes of the cardiac manifestation(s) have been reasonably excluded.</p><p></p><p class="headingAnchor" id="H643630275"><span class="h5">Without histologic confirmation of extracardiac disease</span><span class="headingEndMark"> — </span>A major difficulty in identifying patients with isolated CS is the lack of specificity of symptoms, signs, and imaging findings of CS. Thus, patients with clinical findings and/or imaging findings suggestive of CS without extracardiac sarcoidosis remain in a grey area of diagnostic and prognostic uncertainty. The HRS consensus statement does not include criteria for probable CS in patients without histologic diagnosis of extracardiac sarcoidosis [<a href="#rid2">2</a>]. The authors diagnose "probable CS" in selected patients without histologic confirmation of extracardiac disease who have clinical findings suggesting CS and both CMR and FDG-PET findings typical for CS, when other potential causes for these findings have been excluded via a comprehensive evaluation. Other experts diagnose isolated CS only in patients with myocardial histologic confirmation [<a href="#rid2">2</a>].</p><p>The diagnostic accuracy of advanced imaging was assessed in 42 patients who were studied by CMR (31) and/or FDG-PET (18) prior to cardiac transplantation [<a href="#rid49">49</a>]. Histological assessment of the explanted heart was used as the reference standard.</p><p class="bulletIndent1"><span class="glyph">●</span>FDG-PET: For probable or highly probable FDG-PET findings for CS, the sensitivity was 100 percent (95% CI 54.1-100 percent) and the specificity was 33.3 percent (95% CI 9.9-65.1 percent). For highly probable FDG-PET, the sensitivity was 83.3 percent (95% CI 35.9-99.6 percent) and the specificity was 100 percent (95% CI 73.5-100 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CMR: Data were limited for CMR as only one patient studied by CMR was subsequently found to have CS. The specificity of probable or highly probable CMR findings for CS was 76.7 percent (95% CI 57.7-90.1 percent). The specificity of highly probable CMR was 90 percent (95% CI 73.5-97.9 percent).The evaluation of etiology of cardiomyopathy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a>.)</p><p></p><p class="headingAnchor" id="H1922213169"><span class="h4">Unresolved cases</span><span class="headingEndMark"> — </span>For patients with or without extracardiac sarcoidosis who have a clinical symptom or sign suggestive of CS but lack criteria for definite or probable CS, the likelihood of CS is generally &lt;50 percent, and other alternative diagnoses are more likely to explain the patient’s symptoms. Treatment for CS is not indicated for patients in this category, although serial (eg, annually or twice yearly) follow-up may be appropriate for some patients.</p><p>Management of patients with extracardiac sarcoidosis with no or minor cardiac signs or symptoms is discussed above. (See <a class="local">'Patients without criteria for advanced cardiac imaging'</a> above.)</p><p class="headingAnchor" id="H2596115665"><span class="h2">Comparison of major society guidelines</span><span class="headingEndMark"> — </span>The most commonly used clinical criteria for diagnosing CS are the revised Japanese Ministry of Health and Welfare (JMHW) criteria [<a href="#rid39">39</a>] and the HRS Expert Consensus Statement [<a href="#rid42">42</a>]. Both guidelines provide a histologic pathway whereby a definitive diagnosis of CS can be established by an EMB, which reveals noncaseating granulomas. In patients who do not have a positive EMB, these criteria require a diagnosis of extracardiac sarcoidosis (for the JMHW, this can be either clinical or histologic, while for the HRS criteria, histologic diagnosis of extracardiac sarcoidosis is required) in conjunction with other criteria.</p><p>The most comprehensive document on the role of cardiac PET for detecting CS and using the results for making treatment decisions as well as following the response to therapy has been published as a joint consensus document from the Society of Nuclear Medicine and Molecular Imaging and the American Society of Nuclear Cardiology. This document provides an overview of the indications for cardiac PET, as well as specific details relating to image acquisition and patient preparation [<a href="#rid50">50</a>]. The American Thoracic Society's clinical practice guideline on diagnosis and detection of sarcoidosis also provides information on the role of various diagnostic tests for evaluating patients with suspected sarcoidosis [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H3898522166"><span class="h2">Key diagnostic tests</span></p><p class="headingAnchor" id="H1837953430"><span class="h3">Holter monitoring</span><span class="headingEndMark"> — </span>Continuous ambulatory ECG (Holter) monitoring for 24 hours or more in patients with CS may identify a high burden of ventricular premature beats, nonsustained or sustained VT, AV block, or atrial arrhythmias. Among the commonly used screening tests, ambulatory monitoring has the highest sensitivity (eg, 89 percent), but it has low specificity (21 percent) [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H3044000581"><span class="h3">Echocardiography</span></p><p class="headingAnchor" id="H3012712420"><span class="h4">Echocardiographic findings</span><span class="headingEndMark"> — </span>Echocardiographic findings in patients with CS are variable and may include focal areas of edema resulting in increased wall thickness and mimicking hypertrophic cardiomyopathy (eg, asymmetric septal hypertrophy [<a href="#rid52">52</a>]) or in more advanced patterns of involvement, focal areas of akinesis or dyskinesis, wall thinning, or aneurysm mimicking arrhythmogenic RV cardiomyopathy.</p><p>Among patients with CS, LVEF can be either preserved or reduced. Patients with a dilated cardiomyopathy have dilated LV chambers and depressed LVEF [<a href="#rid53">53</a>]. Patients with a restrictive cardiomyopathy have normal LV chamber sizes and LVEF, and there is evidence of diastolic dysfunction [<a href="#rid54">54</a>]. While patients with CS are at risk for diastolic dysfunction, diastolic dysfunction is a nonspecific finding [<a href="#rid55">55</a>].</p><p>Reduced global longitudinal strain is a feature that may be present in CS with preserved ejection fraction [<a href="#rid56">56</a>], and reduction in longitudinal strain magnitude may vary inversely with LGE burden [<a href="#rid57">57</a>]. Further studies are needed to evaluate the role of strain in screening for CS.</p><p>While echocardiography has a limited sensitivity for detecting CS compared with CMR, it can be useful for evaluating the effects of pulmonary sarcoidosis and CS on hemodynamics and cardiac structure and function including left and RV size and function, valve function, and estimating right heart and pulmonary pressures. Estimation of pulmonary pressures and assessment of RV function may be particularly helpful in patients with pulmonary sarcoidosis.</p><p class="headingAnchor" id="H1703979013"><span class="h4">Limited sensitivity of echocardiography</span><span class="headingEndMark"> — </span>Echocardiography has low sensitivity for detection of CS of approximately 25 to 65 percent as compared with CMR or FDG-PET [<a href="#rid43">43,51,58</a>]. In a study of 321 patients with biopsy-proven sarcoidosis, of whom 30 percent had CS by the HRS criteria, CMR had a sensitivity of 97 percent and detected 44 patients who had symptoms or ECG abnormalities but a normal echocardiogram, as well as 15 asymptomatic patients with normal echocardiogram [<a href="#rid58">58</a>]. Despite a high positive predictive value (84 percent), echocardiography had a low sensitivity (27 percent) to detect CS and, when added to the initial screening based on cardiac history and ECG, did not provide any improvement in sensitivity. Based on the above results, in patients with extracardiac sarcoidosis who have symptoms or signs of possible cardiac involvement, echocardiography should not be used as a screening test, as a negative echocardiogram cannot be used to rule out cardiac involvement.</p><p class="headingAnchor" id="H719873482"><span class="h3">Cardiovascular magnetic resonance</span></p><p class="headingAnchor" id="H536393208"><span class="h4">CMR findings</span><span class="headingEndMark"> — </span>CMR imaging enables the noninvasive diagnosis of subclinical or clinical CS and is the technique of choice in the evaluation of patients with suspected CS. The CMR examination should include assessment of LV and RV chamber size and function and LGE.</p><p>While CMR can detect morphologic abnormalities such as areas of wall thinning or aneurysm, the main CMR method for detecting CS is identification of regions of LGE, which are most commonly multifocal and involve the midventricular wall or subepicardium. LGE most commonly represents scar, although significant inflammation can also result in expansion of the extracellular space leading to LGE. Of note, there is no specific pattern of LGE that is pathognomonic for CS, so careful interpretation in the context of other clinical features is required [<a href="#rid1">1</a>].</p><p>The following are typical LGE patterns in patients with CS [<a href="#rid25">25,59,60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Multifocal areas of LGE (as opposed to a single area).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subepicardial and midmyocardial LGE (ie, noninfarct pattern), although some patients may have subendocardial involvement in a pattern similar to myocardial infarction (MI-type). In a series of patients with extracardiac sarcoidosis, the MI-type pattern was common among the 21 patients with LGE and no obstructive coronary disease but 86 percent of these patients had at least one region with hyperenhancement in a non-MI–type pattern [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct LGE extension from the LV, across the interventricular segment, into the RV.</p><p></p><p>The presence of increased T2 weighted signal, a marker of increased water content, can be used to identify areas of increased inflammation, although this technique is technically challenging [<a href="#rid20">20</a>] and its role in the diagnosis of CS has not been established. Based on our experience, areas of increased T2 signal often represent inflammation, but the absence of such a signal does not reliably exclude inflammation when compared with FDG-PET imaging. Current T2 mapping techniques may overcome some of the challenges of T2 weighted imaging of the myocardium and may provide a more robust method to identify and quantify myocardial inflammation [<a href="#rid61">61,62</a>], but further validation of this technique is required before it can be adopted into routine clinical use.</p><p class="headingAnchor" id="H505248782"><span class="h4">Diagnostic accuracy</span><span class="headingEndMark"> — </span>The main strength of CMR lies in its high negative predictive value for excluding CS when no LGE is detected. The diagnostic accuracy of LGE for detecting CS is unknown, as there is no reliable reference standard, but the sensitivity of this test likely exceeds 90 percent and has been reported to be as high as 100 percent when compared with the JMHW criteria [<a href="#rid63">63</a>]. Similarly, a study evaluating the diagnostic accuracy of CMR against the HRS criteria reported a sensitivity of 97 percent; however, this result was expected based on the study design, which only included patients with biopsy-proven sarcoidosis, and thus all patients with abnormal LGE would be categorized as having "probable CS" by HRS criteria.</p><p>However, the JMHW and HRS criteria for CS may be suboptimal reference standards against which to validate CMR and PET. Apparent false positives using JMHW or HRS criteria are more likely to reflect the limited sensitivity of these criteria (especially for patients without histologic diagnosis), rather than limited specificity of CMR and PET imaging.</p><p>Given the challenges of determining the true diagnostic accuracy of CMR, studies demonstrating the prognostic value of CMR in patients with known or suspected CS provide support for its clinical utility, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'CMR studies'</a>.)</p><p class="headingAnchor" id="H2374874282"><span class="h4">Limitations of CMR</span><span class="headingEndMark"> — </span>Despite the high reported negative predictive value of CMR, there are rare cases when LGE can be negative in the presence of myocardial inflammation, and thus when clinical suspicion is high, a negative LGE exam cannot rule out the presence of CS.</p><p>Although some observations suggest that LGE imaging may be helpful in the assessment of the efficacy of glucocorticoid therapy [<a href="#rid64">64,65</a>], serial imaging is challenging, as patients with CS often require ICD or pacemaker implantation. These cardiac implantable electric devices may cause imaging artifacts, which may interfere with interpretation, and some devices, including most current ICDs, are not magnetic resonance imaging (MRI) compatible. The quality of LGE signal is variable, and LGE signal may be difficult to evaluate, as it often represents concomitant scar and inflammation. CMR is also less useful in assessing for extracardiac sarcoidosis than computed tomography (CT) or FDG-PET imaging.</p><p>Contraindications to CMR (eg, estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73 m<sup>2</sup>, implanted devices that are not MRI safe, severe claustrophobia with inability to sedate the patient) are discussed separately. Gadolinium-containing contrast agents should be avoided in patients with an eGFR &lt;30 mL/min/1.73 m<sup>2</sup>, receiving dialysis, or with acute kidney injury. (See  <a class="medical medical_review" href="/z/d/html/1955.html" rel="external">"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Approach to preventing nephrogenic systemic fibrosis'</a>.)</p><p class="headingAnchor" id="H1592590501"><span class="h3">FDG-PET</span><span class="headingEndMark"> — </span>FDG-PET can detect active myocardial inflammation, which, in the appropriate clinical context, can be used to determine the likelihood of CS. While several studies have tried to determine the diagnostic accuracy of FDG-PET [<a href="#rid66">66,67</a>], these are all limited by the use of the JMHW criteria as a reference standard, which likely has a lower accuracy than FDG-PET itself. Pooled estimates from a meta-analysis of seven studies (with 164 patients) comparing FDG-PET with the 1993 JMHW guidelines included a sensitivity of 89 percent and specificity of 78 percent [<a href="#rid67">67</a>]. FDG-PET is more sensitive than gallium-67 scintigraphy, <a class="drug drug_general" data-topicid="101540" href="/z/d/drug information/101540.html" rel="external">thallium-201</a>, or technicium-99m single-photon emission computed tomography (SPECT) [<a href="#rid66">66,68,69</a>].</p><p>A comprehensive PET imaging exam for CS involves three components:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rest myocardial perfusion imaging</strong> – Rest myocardial perfusion imaging can be obtained with either a SPECT or PET camera. Perfusion defects may represent either fibrosis or inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac FDG-PET images</strong> – Cardiac FDG-PET images require a dedicated PET camera. Areas of focal FDG uptake by the myocardium represent myocardial inflammation. However, this technique requires adequate patient preparation to suppress FDG uptake from the normal myocardium [<a href="#rid50">50,56</a>]. Importantly, FDG uptake by the heart is not specific for sarcoidosis, and uptake of <sup>18</sup>F-FDG is seen in other inflammatory myocardial diseases and hibernating myocardium. For this reason, in the appropriate clinical context, the presence of a resting perfusion defect that has increased FDG uptake requires ruling out obstructive CAD. Our recommendation is to perform either cardiac CT angiography (in lower-risk patients) or invasive angiography, as perfusion imaging will be less specific in such cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracardiac FDG-PET images</strong> – Limited whole-body images are strongly recommended when there are no prior data regarding the presence or disease activity of extracardiac sarcoidosis. The scan range is typically performed from the orbits to the upper thigh, and at minimum should include the chest, liver, and spleen, as these are the most frequently affected organs.</p><p></p><p>The prognostic value of cardiac PET in patients with known or suspected CS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'Cardiac FDG-PET studies'</a>.)</p><p class="headingAnchor" id="H3409256012"><span class="h3">Comparison of CMR with FDG-PET</span><span class="headingEndMark"> — </span>CMR and FDG-PET are the two imaging modalities that appear to have the highest sensitivity for detection of CS [<a href="#rid39">39,40,66,70</a>]. In addition, both CMR and FDG-PET may predict death and other adverse events. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'Advanced cardiac imaging'</a>.)</p><p>There are no adequate studies that are powered to compare the diagnostic accuracy of CMR and PET. Since CMR has an excellent negative predictive value to exclude prognostically significant disease (see  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'CMR studies'</a>), and because it is less likely to yield nonspecific results (as can occur in 10 to 20 percent of FDG-PET cases, particularly when patient preparation is suboptimal), we suggest the use of CMR as the initial diagnostic test for patients with suspected CS who have no contraindications to CMR.</p><p>CMR and PET provide complementary information for many patients with suspected CS. CMR is more likely to provide information regarding the presence and extent of scar, while PET is more likely to provide information regarding the presence, extent, and severity of myocardial inflammation. Therefore, when any one test provides inconclusive results, we suggest combining data from both of these exams in order to determine the likelihood of CS [<a href="#rid71">71-74</a>]. (See <a class="local">'Selection of advanced imaging'</a> above.)</p><p class="headingAnchor" id="H1194347712"><span class="h3">Endomyocardial biopsy</span><span class="headingEndMark"> — </span>Detecting noncaseating granulomas is the "gold standard" for diagnosis of CS, as this finding has high specificity for sarcoidosis  (<a class="graphic graphic_picture graphicRef63327" href="/z/d/graphic/63327.html" rel="external">picture 1</a>). An EMB is recommended if the patient lacks histologic confirmation of noncaseating granulomas from any other source. However, the procedure has a low sensitivity, approaching 20 percent in one series of 26 patients [<a href="#rid75">75</a>]. Its use is limited by false negative results owing to sampling error that may occur due to the patchy distribution of disease. EMB is most commonly performed from the RV at the midmyocardial level, while disease involvement is more common in the basal septum and lateral LV wall, regions that are difficult to biopsy. Given the restricted area of RV midmyocardium that is safely accessible to traditional transvenous cardiac biopsy, there is only a limited role for using CMR or PET findings to guide biopsy. However, during electrophysiology (EP) study when there is suspected CS (see <a class="local">'Electrophysiologic study'</a> below), electroanatomic mapping can be used to identify areas of low voltage which may correspond to granuloma and may be targeted for biopsy, thereby increasing the diagnostic yield [<a href="#rid76">76,77</a>]. (See  <a class="medical medical_review" href="/z/d/html/4923.html" rel="external">"Endomyocardial biopsy", section on 'Late AV block, arrhythmias, or refractory HF'</a>.)</p><p class="headingAnchor" id="H3796924981"><span class="h2">Additional tests</span><span class="headingEndMark"> — </span>EP study or coronary angiography is indicated in the evaluation of only selected patients with suspected or known CS.</p><p class="headingAnchor" id="H206457286"><span class="h3">Coronary angiography</span><span class="headingEndMark"> — </span>Cardiac catheterization with coronary angiography (or in younger patients with a lower likelihood of CAD, coronary CT angiography) is useful in excluding the diagnosis of atherosclerotic CAD when other testing such as CMR or PET reveals regional myocardial abnormalities that could be caused by coronary disease or sarcoidosis.</p><p>Primary sarcoidosis rarely involves the coronary arteries [<a href="#rid78">78</a>]. Although granulomatous vasculitis may cause partial or complete narrowing of the epicardial coronary arteries, thrombosis and aneurysm formation are rare. Perfusion defects in patients with known systemic sarcoidosis strongly suggest cardiac involvement if coronary angiography has excluded significant atherosclerosis. (See <a class="local">'Other tests'</a> below.)</p><p class="headingAnchor" id="H3980403966"><span class="h3">Electrophysiologic study</span><span class="headingEndMark"> — </span>While EP studies are not routinely performed for the diagnosis of CS, many patients with suspected CS undergo EP studies for risk stratification as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis", section on 'Role of electrophysiologic study'</a>.)</p><p class="headingAnchor" id="H2607145733"><span class="h3">Other tests</span><span class="headingEndMark"> — </span>The following tests are not generally indicated in the diagnostic evaluation of CS:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nuclear myocardial perfusion imaging</strong> – Nuclear myocardial perfusion imaging is not indicated for the diagnosis of CS. However, it is important to be aware of myocardial perfusion abnormalities that may be detected in patients evaluated for CAD that may instead be caused by CS. Among patients with CS, rest nuclear myocardial perfusion imaging findings include a resting perfusion defect, with the most common locations being the basal anteroseptal, basal lateral, or basal inferior wall. Such perfusion defects, which represent scar or inflammation compressing the microvasculature, may improve following immunosuppressive therapy. However, the presence of normal myocardial perfusion at rest does not exclude the presence of CS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiopulmonary exercise testing</strong> – Reduced oxygen uptake efficiency slope (a measure of cardiopulmonary functional reserve that is derived from the oxygen uptake and minute ventilation) has been found to have a modest sensitivity and specificity to detect CS [<a href="#rid79">79</a>]. The role of cardiopulmonary exercise testing in assessment of patients with HF is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3503.html" rel="external">"Exercise capacity and VO2 in heart failure"</a>.)</p><p></p><p class="headingAnchor" id="H1862479501"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>CS should be carefully distinguished from other conditions with similar clinical presentations or cardiac imaging findings including myocarditis, other types of conduction system disease, cardiomyopathies, and ischemic heart disease. CS, Lyme carditis, and giant cell myocarditis all may present with conduction system disease. Giant cell myocarditis, often presenting with AV block, unstable ventricular arrhythmias, and acute HF, should be considered, particularly when there is a more acute or fulminant clinical presentation. Patients with myocarditis may have symptoms suggestive of a viral prodrome (eg, fever and myalgias) and are more likely to present with elevated cardiac troponin levels, but these features do not reliably distinguish between CS and myocarditis, as a viral prodrome is often absent in patients with myocarditis, and troponin elevation is common in patients with CS. Studies suggest that <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography (FDG-PET) abnormalities are common in patients with myocarditis (including giant cell myocarditis) and also have been observed in patients with cardiomyopathy (including arrhythmogenic RV cardiomyopathy) [<a href="#rid80">80-83</a>]. Patients with myocarditis may also have evidence of scar on magnetic resonance imaging (MRI) indistinguishable from that seen with CS. Endomyocardial biopsy may be required to distinguish these conditions. (See  <a class="medical medical_review" href="/z/d/html/4939.html" rel="external">"Clinical manifestations and diagnosis of myocarditis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4923.html" rel="external">"Endomyocardial biopsy"</a>.)</p><p>The differential diagnosis of CS also includes other causes of AV block such as idiopathic progressive cardiac conduction disease and genetically determined arrhythmias such as SCN5A and lamin A/C disease. (See  <a class="medical medical_review" href="/z/d/html/907.html" rel="external">"Etiology of atrioventricular block", section on 'Pathophysiologic AV block'</a>.)</p><p>Arrhythmogenic RV cardiomyopathy (ARVC) can also mimic CS (and vice versa) and can be challenging to differentiate [<a href="#rid49">49,84</a>]. Although early descriptions and diagnostic criteria for ARVC focused on the clinical features of RV involvement, the majority of patients with this disorder also have electrocardiographic, arrhythmic, and/or imaging evidence of LV involvement, and like CS, disease may involve the LV, RV, or both ventricles [<a href="#rid85">85,86</a>]. Useful distinguishing features between ARVC and CS include the presence of familial disease in ARVC, first-degree or higher AV block favoring the diagnosis of CS, and epi- and/or midmyocardial circumferential late gadolinium enhancement (LGE) favoring ARVC with LV involvement or one of the other inherited arrhythmogenic cardiomyopathies [<a href="#rid87">87-89</a>]. While not a criterion on the 2010 Task Force Criteria for ARVC, the presence of significant fat in the myocardium would also favor the diagnosis of ARVC. Electroanatomic voltage mapping may also be used to distinguish ARVC from isolated CS in patients presenting with right-sided ventricular arrhythmias [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/110459.html" rel="external">"Arrhythmogenic right ventricular cardiomyopathy: Diagnostic evaluation and diagnosis"</a>.)</p><p>On imaging, CS may present with areas of increased wall thickness or areas of wall thinning and even aneurysm, and thus must be distinguished from other conditions with similar abnormalities. Fabry disease, a rare inherited disorder of fat metabolism, can present with concentric or asymmetric LV hypertrophy, and on MRI often has midwall LGE of the basal inferolateral wall (see  <a class="medical medical_review" href="/z/d/html/4914.html" rel="external">"Fabry disease: Cardiovascular disease", section on 'Cardiac tests'</a>). While such LGE findings can also be seen in CS, CS is more likely to have multifocal LGE and focal areas of LV hypertrophy. LV noncompaction may present with ventricular arrhythmia and increased wall thickness much like CS, but in noncompaction increased trabeculations of the ventricular myocardium are detected on echocardiography or cardiac magnetic resonance (CMR) (see  <a class="medical medical_review" href="/z/d/html/4924.html" rel="external">"Isolated left ventricular noncompaction in adults: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>). Cardiac iron overload from hereditary hemochromatosis can present with conduction disease, arrhythmia, and HF much like CS, but hemochromatosis may be accompanied by diabetes and bronze skin and can be diagnosed by reduced T2* signal on CMR (see  <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">"Approach to the patient with suspected iron overload"</a>). In rare cases, CS may also resemble end-stage hypertrophic cardiomyopathy where there is significant replacement fibrosis of the LV. (See  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Diagnostic evaluation'</a>.)</p><p>Right HF due to CS involving the RV should be distinguished from other causes of right HF such as right HF secondary to left HF (which may be caused by CS) and right HF caused by pulmonary sarcoidosis (cor pulmonale). (See <a class="local">'Cardiomyopathy and heart failure'</a> above.)</p><p>Cor pulmonale secondary to pulmonary sarcoidosis should be distinguished from CS involving the RV. Pulmonary hypertension is a complication in some patients (estimated at 3 to 20 percent) with pulmonary sarcoidosis [<a href="#rid91">91</a>] and often occurs in the absence of CS. Some patients with pulmonary hypertension may develop right HF. Patients who have pulmonary sarcoidosis with cor pulmonale can have areas of focal LGE on MRI at the RV insertion points. Such findings are well described in patients with pulmonary hypertension and should be distinguished from CS where the LGE involvement is more extensive, and often extends beyond the insertion points to involve the RV and LV.</p><p>While most patients with CS have subepicardial or midwall LGE involvement on MRI, some can have subendocardial LGE, which is a pattern most commonly seen in patients who have had prior myocardial infarctions. Similarly, CS may be detected on FDG-PET by a rest perfusion defect associated with increased FDG uptake. However, such a pattern can also be seen in patients with hibernating myocardium, and thus the presence of obstructive coronary artery disease should be ruled out in such scenarios. (See  <a class="medical medical_review" href="/z/d/html/1474.html" rel="external">"Evaluation of hibernating myocardium"</a> and  <a class="medical medical_review" href="/z/d/html/1527.html" rel="external">"Clinical syndromes of stunned or hibernating myocardium"</a> and  <a class="medical medical_review" href="/z/d/html/1507.html" rel="external">"Treatment of ischemic cardiomyopathy"</a>.)</p><p>Other diseases that can mimic CS include Chagas disease and tuberculosis. Both can cause cardiac aneurysms and ventricular arrhythmias. (See  <a class="medical medical_review" href="/z/d/html/4955.html" rel="external">"Chronic Chagas cardiomyopathy: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1029.html" rel="external">"Sustained monomorphic ventricular tachycardia: Clinical manifestations, diagnosis, and evaluation", section on 'Epidemiology and risk factors'</a>.)</p><p>Genetic cardiomyopathies, including those caused by mutations in desmosomal and lamin A/C protein genes, share some clinical characteristics with CS but have differing histologic characteristics. Genetic testing may be particularly useful in unresolved cases of suspected sarcoid without histologic confirmation, particularly when clinical manifestations and imaging abnormalities are isolated to the heart. (See  <a class="medical medical_review" href="/z/d/html/4911.html" rel="external">"Genetics of dilated cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H2671431085"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116637.html" rel="external">"Society guideline links: Sarcoidosis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115415.html" rel="external">"Society guideline links: Myocarditis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/115416.html" rel="external">"Society guideline links: Cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H3561499069"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac sarcoidosis (CS) is common, occurring in 20 percent or more of patients with systemic sarcoidosis, but the true prevalence remains unknown and is likely underestimated since many individuals with CS may have nonspecific symptoms or subclinical disease. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Up to 25 percent of cases of CS are isolated (occur without extracardiac involvement), and thus absence of extracardiac sarcoidosis does not exclude CS. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical presentation of CS ranges from an incidentally discovered condition to syncope, heart failure, and sudden death. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with extracardiac sarcoidosis who lack one or more of the symptoms and signs of CS that serve as indications for advanced imaging are unlikely to benefit from further immediate evaluation. Serial (eg, annual) cardiac examinations and electrocardiograms are recommended to detect development of symptoms or signs of CS. (See <a class="local">'Patients without criteria for advanced cardiac imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of CS requires appropriate clinical suspicion and often requires integrating clinical and pathologic data together with the results of advanced cardiac imaging. Diagnostic certainty of CS ranges from "definite" to "probable" (≥50 percent). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have known extracardiac sarcoidosis, characteristic cardiac magnetic resonance imaging (CMR) or <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography (FDG-PET) findings can be used to confirm the diagnosis of CS. Endomyocardial biopsy is often not required. (See <a class="local">'How to diagnose cardiac sarcoidosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the absence of biopsy-proven extracardiac sarcoidosis, or when data are inconclusive, integrating data from CMR imaging and FDG-PET may be useful for establishing the likelihood of CS. (See <a class="local">'Uncertain diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H4216286142"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thanks Talmadge King Jr., MD, who contributed as section editor to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Roberts WC, Chung MS, Ko JM, et al. Morphologic features of cardiac sarcoidosis in native hearts of patients having cardiac transplantation. Am J Cardiol 2014; 113:706.</a></li><li><a class="nounderline abstract_t">Okada DR, Bravo PE, Vita T, et al. Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. J Nucl Cardiol 2018; 25:1136.</a></li><li><a class="nounderline abstract_t">Birnie D, Ha AC, Gula LJ, et al. Cardiac Sarcoidosis. Clin Chest Med 2015; 36:657.</a></li><li><a class="nounderline abstract_t">Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978; 58:1204.</a></li><li><a class="nounderline abstract_t">Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993; 103:253.</a></li><li><a class="nounderline abstract_t">Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci 1976; 278:455.</a></li><li><a class="nounderline abstract_t">Yigla M, Badarna-Abu-Ria N, Tov N, et al. Sarcoidosis in northern Israel; clinical characteristics of 120 patients. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:220.</a></li><li><a class="nounderline abstract_t">Yafasova A, Fosbøl EL, Schou M, et al. Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. J Am Coll Cardiol 2020; 76:767.</a></li><li><a class="nounderline abstract_t">Yafsova A. Long-term adverse cardiac outcomes in patients with sarcoidosis. J Am Coll Cardiol 2020; 76:767.</a></li><li><a class="nounderline abstract_t">Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015; 131:624.</a></li><li><a class="nounderline abstract_t">Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011; 270:461.</a></li><li><a class="nounderline abstract_t">Hulten E, Aslam S, Osborne M, et al. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther 2016; 6:50.</a></li><li><a class="nounderline abstract_t">Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014; 25:875.</a></li><li class="breakAll">Fleming H. Cardiac Sarcoidosis. In: Sarcoidosis and Other Granulomatous Disorders, James DG (Ed), Dekker, New York 1994. p.323.</li><li><a class="nounderline abstract_t">Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 2004; 83:315.</a></li><li><a class="nounderline abstract_t">Yoshida Y, Morimoto S, Hiramitsu S, et al. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J 1997; 134:382.</a></li><li><a class="nounderline abstract_t">Narasimhan B, Patel N, Ho K, et al. Incidence and Predictors of Sudden Cardiac Arrest in Sarcoidosis: A Nationwide Analysis. JACC Clin Electrophysiol 2021; 7:1087.</a></li><li><a class="nounderline abstract_t">Weng W, Wiefels C, Chakrabarti S, et al. Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes. J Am Heart Assoc 2020; 9:e017086.</a></li><li><a class="nounderline abstract_t">Viles-Gonzalez JF, Pastori L, Fischer A, et al. Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. Chest 2013; 143:1085.</a></li><li><a class="nounderline abstract_t">Cain MA, Metzl MD, Patel AR, et al. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol 2014; 113:1556.</a></li><li><a class="nounderline abstract_t">Schaedel H, Kirsten D, Schmidt A, et al. Sarcoid heart disease--results of follow-up investigations. Eur Heart J 1991; 12 Suppl D:26.</a></li><li><a class="nounderline abstract_t">Schulte W, Kirsten D, Drent M, Costabel U. Cardiac involvement in sarcoidosis. Eur Respir Mon 2005; 32:130.</a></li><li><a class="nounderline abstract_t">Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:75.</a></li><li><a class="nounderline abstract_t">Ekström K, Lehtonen J, Nordenswan HK, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J 2019; 40:3121.</a></li><li><a class="nounderline abstract_t">Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120:1969.</a></li><li><a class="nounderline abstract_t">Webb M, Conway KS, Ishikawa M, Diaz F. Cardiac Involvement in Sarcoidosis Deaths in Wayne County, Michigan: A 20-Year Retrospective Study. Acad Forensic Pathol 2018; 8:718.</a></li><li><a class="nounderline abstract_t">Rosenthal DG, Fang CD, Groh CA, et al. Heart Failure, Atrioventricular Block, and Ventricular Tachycardia in Sarcoidosis. J Am Heart Assoc 2021; 10:e017692.</a></li><li><a class="nounderline abstract_t">Joyce E, Kamperidis V, Ninaber MK, et al. Prevalence and Correlates of Early Right Ventricular Dysfunction in Sarcoidosis and Its Association with Outcome. J Am Soc Echocardiogr 2016; 29:871.</a></li><li><a class="nounderline abstract_t">Patel MB, Mor-Avi V, Murtagh G, et al. Right Heart Involvement in Patients with Sarcoidosis. Echocardiography 2016; 33:734.</a></li><li><a class="nounderline abstract_t">Velangi PS, Chen KA, Kazmirczak F, et al. Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis. JACC Cardiovasc Imaging 2020; 13:1395.</a></li><li><a class="nounderline abstract_t">Lønborg J, Ward M, Gill A, et al. Utility of cardiac magnetic resonance in assessing right-sided heart failure in sarcoidosis. BMC Med Imaging 2013; 13:2.</a></li><li><a class="nounderline abstract_t">Goyal SB, Aragam JR. Cardiac sarcoidosis with primary involvement of the tricuspid valve. Cardiol Rev 2006; 14:e12.</a></li><li><a class="nounderline abstract_t">Lam CS, Tolep KA, Metke MP, et al. Coronary sarcoidosis presenting as acute coronary syndrome. Clin Cardiol 2009; 32:E68.</a></li><li><a class="nounderline abstract_t">Ward EV, Nazari J, Edelman RR. Coronary artery vasculitis as a presentation of cardiac sarcoidosis. Circulation 2012; 125:e344.</a></li><li><a class="nounderline abstract_t">Butany J, Bahl NE, Morales K, et al. The intricacies of cardiac sarcoidosis: a case report involving the coronary arteries and a review of the literature. Cardiovasc Pathol 2006; 15:222.</a></li><li><a class="nounderline abstract_t">Kandolin R, Ekström K, Simard T, et al. Spontaneous coronary artery dissection in cardiac sarcoidosis. Oxf Med Case Reports 2019; 2019:omz033.</a></li><li><a class="nounderline abstract_t">Hamzeh N, Steckman DA, Sauer WH, Judson MA. Pathophysiology and clinical management of cardiac sarcoidosis. Nat Rev Cardiol 2015; 12:278.</a></li><li><a class="nounderline abstract_t">Kandolin R, Lehtonen J, Airaksinen J, et al. Usefulness of Cardiac Troponins as Markers of Early Treatment Response in Cardiac Sarcoidosis. Am J Cardiol 2015; 116:960.</a></li><li><a class="nounderline abstract_t">Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009; 20:578.</a></li><li><a class="nounderline abstract_t">Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart 2011; 97:2078.</a></li><li><a class="nounderline abstract_t">Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol 2017; 24:1741.</a></li><li><a class="nounderline abstract_t">Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11:1305.</a></li><li><a class="nounderline abstract_t">Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133:1426.</a></li><li><a class="nounderline abstract_t">Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201:e26.</a></li><li><a class="nounderline abstract_t">Writing group, Document reading group, EACVI Reviewers: This document was reviewed by members of the EACVI
                    Scientific Documents Committee for 2014–2016 and 2016–2018. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation &amp; Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. Eur Heart J Cardiovasc Imaging 2017; 18:1073.</a></li><li><a class="nounderline abstract_t">Zhou Y, Lower EE, Li HP, et al. Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival. Chest 2017; 151:139.</a></li><li><a class="nounderline abstract_t">Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:19.</a></li><li><a class="nounderline abstract_t">Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.</a></li><li><a class="nounderline abstract_t">Divakaran S, Stewart GC, Lakdawala NK, et al. Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. Circ Cardiovasc Imaging 2019; 12:e008975.</a></li><li><a class="nounderline abstract_t">Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. J Nucl Med 2017; 58:1341.</a></li><li><a class="nounderline abstract_t">Freeman AM, Curran-Everett D, Weinberger HD, et al. Predictors of cardiac sarcoidosis using commonly available cardiac studies. Am J Cardiol 2013; 112:280.</a></li><li><a class="nounderline abstract_t">Agarwal A, Sulemanjee NZ, Cheema O, et al. Cardiac sarcoid: a chameleon masquerading as hypertrophic cardiomyopathy and dilated cardiomyopathy in the same patient. Echocardiography 2014; 31:E138.</a></li><li><a class="nounderline abstract_t">Adlan AM, Prasad SK, Varnava AM. Sarcoidosis presenting as dilated cardiomyopathy. Heart 2011; 97:1896.</a></li><li><a class="nounderline abstract_t">Nihoyannopoulos P, Dawson D. Restrictive cardiomyopathies. Eur J Echocardiogr 2009; 10:iii23.</a></li><li><a class="nounderline abstract_t">Patel AR, Klein MR, Chandra S, et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail 2011; 13:1231.</a></li><li><a class="nounderline abstract_t">Murtagh G, Laffin LJ, Patel KV, et al. Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction. Echocardiography 2016; 33:1344.</a></li><li><a class="nounderline abstract_t">Milman N, Andersen CB, Mortensen SA, Sander K. Cardiac sarcoidosis and heart transplantation: a report of four consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25:51.</a></li><li><a class="nounderline abstract_t">Kouranos V, Tzelepis GE, Rapti A, et al. Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis. JACC Cardiovasc Imaging 2017; 10:1437.</a></li><li><a class="nounderline abstract_t">Sharma S. Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. Curr Opin Pulm Med 2009; 15:507.</a></li><li><a class="nounderline abstract_t">Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013; 6:501.</a></li><li><a class="nounderline abstract_t">Puntmann VO, Isted A, Hinojar R, et al. T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis. Radiology 2017; 285:63.</a></li><li><a class="nounderline abstract_t">Crouser ED, Ono C, Tran T, et al. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med 2014; 189:109.</a></li><li><a class="nounderline abstract_t">Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45:1683.</a></li><li><a class="nounderline abstract_t">Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 1996; 10:495.</a></li><li><a class="nounderline abstract_t">Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 2002; 122:1895.</a></li><li><a class="nounderline abstract_t">Ishimaru S, Tsujino I, Sakaue S, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:234.</a></li><li><a class="nounderline abstract_t">Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53:241.</a></li><li><a class="nounderline abstract_t">Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009; 16:801.</a></li><li><a class="nounderline abstract_t">Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45:1989.</a></li><li><a class="nounderline abstract_t">Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009; 157:9.</a></li><li><a class="nounderline abstract_t">Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis. Circ Cardiovasc Imaging 2018; 11:e007030.</a></li><li><a class="nounderline abstract_t">Sgard B, Brillet PY, Bouvry D, et al. Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis. Clin Radiol 2019; 74:81.e9.</a></li><li><a class="nounderline abstract_t">Dweck MR, Abgral R, Trivieri MG, et al. Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis. JACC Cardiovasc Imaging 2018; 11:94.</a></li><li><a class="nounderline abstract_t">Bravo PE, Raghu G, Rosenthal DG, et al. Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. Int J Cardiol 2017; 241:457.</a></li><li><a class="nounderline abstract_t">Uemura A, Morimoto S, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999; 138:299.</a></li><li><a class="nounderline abstract_t">Liang JJ, Hebl VB, DeSimone CV, et al. Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. JACC Heart Fail 2014; 2:466.</a></li><li><a class="nounderline abstract_t">Vaidya VR, Abudan AA, Vasudevan K, et al. The efficacy and safety of electroanatomic mapping-guided endomyocardial biopsy: a systematic review. J Interv Card Electrophysiol 2018; 53:63.</a></li><li><a class="nounderline abstract_t">Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138:1078.</a></li><li><a class="nounderline abstract_t">Ammenwerth W, Wurps H, Klemens MA, et al. Reduced oxygen uptake efficiency slope in patients with cardiac sarcoidosis. PLoS One 2014; 9:e102333.</a></li><li><a class="nounderline abstract_t">Lamacie MM, Almufleh A, Nair V, et al. Serial 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging in a Patient With Giant Cell Myocarditis. Circ Cardiovasc Imaging 2020; 13:e009940.</a></li><li><a class="nounderline abstract_t">Nensa F, Kloth J, Tezgah E, et al. Feasibility of FDG-PET in myocarditis: Comparison to CMR using integrated PET/MRI. J Nucl Cardiol 2018; 25:785.</a></li><li><a class="nounderline abstract_t">Chen W, Jeudy J. Assessment of Myocarditis: Cardiac MR, PET/CT, or PET/MR? Curr Cardiol Rep 2019; 21:76.</a></li><li><a class="nounderline abstract_t">Hanneman K, Kadoch M, Guo HH, et al. Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis. Clin Nucl Med 2017; 42:e328.</a></li><li><a class="nounderline abstract_t">Gasperetti A, Rossi VA, Chiodini A, et al. Differentiating hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis fulfilling 2010 ARVC Task Force Criteria. Heart Rhythm 2021; 18:231.</a></li><li><a class="nounderline abstract_t">McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994; 71:215.</a></li><li><a class="nounderline abstract_t">Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm 2019; 16:e301.</a></li><li><a class="nounderline abstract_t">Philips B, Madhavan S, James CA, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol 2014; 7:230.</a></li><li><a class="nounderline abstract_t">Norman M, Simpson M, Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 2005; 112:636.</a></li><li><a class="nounderline abstract_t">Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol 2008; 52:2175.</a></li><li><a class="nounderline abstract_t">Hoogendoorn JC, Sramko M, Venlet J, et al. Electroanatomical Voltage Mapping to Distinguish Right-Sided Cardiac Sarcoidosis From Arrhythmogenic Right Ventricular Cardiomyopathy. JACC Clin Electrophysiol 2020; 6:696.</a></li><li><a class="nounderline abstract_t">Huitema MP, Grutters JC, Rensing BJWM, et al. Pulmonary hypertension complicating pulmonary sarcoidosis. Neth Heart J 2016; 24:390.</a></li></ol></div><div id="topicVersionRevision">Topic 4922 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24393258" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Morphologic features of cardiac sarcoidosis in native hearts of patients having cardiac transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27613395" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Isolated cardiac sarcoidosis: A focused review of an under-recognized entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26593140" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cardiac Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/709777" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8417889" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Myocardial sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1067031" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinicopathological study of fatal myocardial sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12405492" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sarcoidosis in northern Israel; clinical characteristics of 120 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32792073" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term adverse cardiac outcomes in patients with sarcoidosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25527698" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21535250" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diagnosing isolated cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26885492" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cardiac sarcoidosis-state of the art review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602015" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602015" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15525844" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cardiac sarcoidosis: a retrospective study of 41 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9327691" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33812830" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence and Predictors of Sudden Cardiac Arrest in Sarcoidosis: A Nationwide Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32814465" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23667912" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24731652" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1915455" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Sarcoid heart disease--results of follow-up investigations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cardiac involvement in sarcoidosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10207945" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31230070" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884472" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Detection of myocardial damage in patients with sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31240066" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cardiac Involvement in Sarcoidosis Deaths in Wayne County, Michigan: A 20-Year Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33599141" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Heart Failure, Atrioventricular Block, and Ventricular Tachycardia in Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27450364" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence and Correlates of Early Right Ventricular Dysfunction in Sarcoidosis and Its Association with Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26773449" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Right Heart Involvement in Patients with Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31954639" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23311586" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Utility of cardiac magnetic resonance in assessing right-sided heart failure in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924157" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cardiac sarcoidosis with primary involvement of the tricuspid valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19330817" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Coronary sarcoidosis presenting as acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22331924" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Coronary artery vasculitis as a presentation of cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16844554" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The intricacies of cardiac sarcoidosis: a case report involving the coronary arteries and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31198569" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Spontaneous coronary artery dissection in cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25707386" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pathophysiology and clinical management of cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209113" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Usefulness of Cardiac Troponins as Markers of Early Treatment Response in Cardiac Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19175448" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22116891" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28770463" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24819193" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339784" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293205" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28984894" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation&amp;Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27614001" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24751450" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430755" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31177817" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28765228" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602692" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Predictors of cardiac sarcoidosis using commonly available cardiac studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24506439" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cardiac sarcoid: a chameleon masquerading as hypertrophic cardiomyopathy and dilated cardiomyopathy in the same patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903970" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sarcoidosis presenting as dilated cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19889655" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Restrictive cardiomyopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810833" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27677642" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19070261" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cardiac sarcoidosis and heart transplantation: a report of four consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28330653" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19542892" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23498675" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448233" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24381994" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15893188" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8950063" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12475823" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16315788" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22228794" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19548047" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585472" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081391" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29335272" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482560" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Evaluation of FDG PET combined with cardiac MRI for the diagnosis and therapeutic monitoring of cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28624396" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28318664" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10426842" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25194292" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30003460" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The efficacy and safety of electroanatomic mapping-guided endomyocardial biopsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20348196" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25029031" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Reduced oxygen uptake efficiency slope in patients with cardiac sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32000512" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Serial 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging in a Patient With Giant Cell Myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27638745" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Feasibility of FDG-PET in myocarditis: Comparison to CMR using integrated PET/MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31243587" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Assessment of Myocarditis: Cardiac MR, PET/CT, or PET/MR?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418949" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32976989" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Differentiating hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis fulfilling 2010 ARVC Task Force Criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8142187" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31078652" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24585727" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16061754" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19095136" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32553221" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Electroanatomical Voltage Mapping to Distinguish Right-Sided Cardiac Sarcoidosis From Arrhythmogenic Right Ventricular Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27194118" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pulmonary hypertension complicating pulmonary sarcoidosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
